Transparency notifications BlackRock, Inc.

Brussels (Belgium), 23 May 2017 – 20:10 (CEST) – regulated information

1.    Summary of the notifications

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 4 transparency notifications, dated 17, 18,19 and 22 May 2017 respectively, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.). 

In the first notification, BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and has crossed downward the 3% threshold of voting rights on 16 May 2017.

In the second notification, BlackRock, Inc. has informed that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has increased and has crossed the 3% threshold of voting rights again on 17 May 2017.

In the third notification, BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and has crossed downward the 3% threshold of voting rights on 18 May 2017.

In the last notification, BlackRock, Inc. has informed that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has increased and has crossed the 3% threshold of voting rights again on 19 May 2017.

On 16 May 2017, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 795 762 UCB shares with voting rights (versus 5 848 791 UCB shares in its previous notification dated 15 May 2017), representing 2.98% of the total number of shares issued by the company (194 505 658) (versus 3.01% in the notification dated 15 May 2017). 

On 19 May 2017, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 937 205 UCB shares with voting rights, representing 3.05% of the total number of shares issued by the company.

2.    Content of the notifications

The information mentioned hereafter was identical in all these notifications:

• Reason for the notification: Acquisition or disposal of voting securities or voting rights.
• Notification by: A parent undertaking or a controlling person.
• Threshold crossed (in %): 3%.
• Denominator: 194 505 658.
• Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the PDF which is attached to the notifications.

The transparency notification dated 17 May 2017 includes the following specific information:

• Persons subject to the notification requirement: 

• Date on which the threshold is crossed: 16 May 2017.
• Notified details:

• Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going below 3%.

The transparency notification dated 18 May 2017 includes the following specific information:

• Persons subject to the notification requirement:

• Date on which the threshold is crossed: 17 May 2017.
• Notified details:

• Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 3%.

The transparency notification dated 19 May 2017 includes the following information:

• Persons subject to the notification requirement:

• Date on which the threshold is crossed: 18 May 2017.
• Notified details:

• Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going below 3%.

The transparency notification dated 22 May 2017 includes the following information:

• Persons subject to the notification requirement:

• Date on which the threshold is crossed: 19 May 2017.
• Notified details:

• Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 3%.

3.    Further information 

This press release and the detailed transparency notifications are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

Investor Relations

Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news